Home » MEDTRONIC 'BUY'
MEDTRONIC 'BUY'
Analyst Glenn Novoarro of Banc of America Securities maintains his "buy"
rating on Medtronic. The target price is set to $62. In a research note published
this morning, the analyst mentions that the pivotal drug-eluting stent trial
data for Endeavor III is expected to be released on Oct. 17.
Newratings
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May